<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483324</url>
  </required_header>
  <id_info>
    <org_study_id>AB-110-001</org_study_id>
    <nct_id>NCT03483324</nct_id>
  </id_info>
  <brief_title>Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation</brief_title>
  <official_title>A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiocrine Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Angiocrine Bioscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies,&#xD;
      including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and&#xD;
      myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive&#xD;
      unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor&#xD;
      cells (HSPC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events grade 4 or grade 5 as assessed by CTCAEv4</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sustained donor-derived neutrophil engraftment</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sustained donor-derived neutrophil engraftment</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sustained donor-derived neutrophil engraftment</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of engraftment syndrome</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of post-transplant phenotype in hematopoietic cells of donor origin</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade II - IV acute graft versus host disease (aGVHD)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade II - IV acute graft versus host disease (GVHD)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lymphoid recovery</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant related mortality (TRM)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant related mortality (TRM)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Late onset acute GVHD</measure>
    <time_frame>720 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>720 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative recovery of T-cells and subsets</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative recovery of T-cells and subsets</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence of malignancy</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence of malignancy</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Other Acute Leukemias</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unmanipulated umbilical cord blood plus AB-110</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Unmanipulated Umbilical Cord Blood (UCB)</intervention_name>
    <description>Human leukocyte antigen (HLA) matched umbilical cord blood</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AB-110</intervention_name>
    <description>Expanded cord blood stem cells and engineered human endothelial cells</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have received some immunosuppressive chemotherapy in the preceding 3&#xD;
             months.&#xD;
&#xD;
          -  Acute myelogenous leukemia (AML):&#xD;
&#xD;
               1. Complete first remission (CR1) at high risk for relapse&#xD;
&#xD;
               2. Complete second remission (CR2).&#xD;
&#xD;
               3. No documented myelofibrosis at screening marrow biopsy&#xD;
&#xD;
          -  Acute lymphoblastic leukemia (ALL):&#xD;
&#xD;
               1. Complete first remission (CR1) at high risk for relapse&#xD;
&#xD;
               2. Complete second remission (CR2).&#xD;
&#xD;
          -  Other acute leukemias that are of ambiguous lineage or of other types&#xD;
&#xD;
          -  Any acute leukemia with marrow aplasia or without adequate count recovery.&#xD;
&#xD;
          -  Myelodysplastic Syndrome (MDS)&#xD;
&#xD;
          -  Karnofsky score &gt; 70 %.&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 60 ml/min.&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL, ALT &lt; 3 x upper limit of normal&#xD;
&#xD;
          -  Pulmonary function (FVC, FEV1 and corrected DLCO) &gt; 50% predicted.&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 50%.&#xD;
&#xD;
          -  Albumin &gt; 3.0 g/dL.&#xD;
&#xD;
          -  Negative antiviral serology:&#xD;
&#xD;
          -  Negative human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Negative human T-lymphotropic virus (HTLV)-1 and 2 antibodies.&#xD;
&#xD;
          -  Negative hepatitis B surface antigen (HBsAg) and undetectable hepatitis B virus (HBV)&#xD;
             DNA&#xD;
&#xD;
          -  Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)&#xD;
&#xD;
          -  For female subjects of childbearing potential:&#xD;
&#xD;
               1. A negative serum pregnancy test&#xD;
&#xD;
               2. Willing to use contraception throughout the study period.&#xD;
&#xD;
          -  Male subjects must be willing to use a recommended method of contraception throughout&#xD;
             the study period, and to refrain from sperm donation throughout the study period.&#xD;
&#xD;
          -  Two appropriate CB units identified for the subject.&#xD;
&#xD;
          -  In the judgment of the investigator, participation in the protocol offers an&#xD;
             acceptable benefit-to-risk ratio when considering current disease status, medical&#xD;
             condition, and the potential benefits and risks of alternative treatments for the&#xD;
             subject's cancer.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, drug administration plan,&#xD;
             protocol-specified laboratory tests, other study procedures, and study restrictions.&#xD;
&#xD;
          -  Evidence of a signed informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Current active, uncontrolled bacterial, viral, or fungal infection&#xD;
&#xD;
          -  Prior allogeneic or autologous HCT at any time.&#xD;
&#xD;
          -  Active malignancy other than the one for which AB-110 transplant is being performed&#xD;
             within 12 months of enrollment.&#xD;
&#xD;
          -  Any identified and available 10/10 HLA-matched related donor or 10/10 HLA-matched&#xD;
             unrelated donor.&#xD;
&#xD;
          -  Have evidence of recipient donor specific anti-HLA antibodies.&#xD;
&#xD;
          -  Active central nervous system (CNS) disease at time of screening.&#xD;
&#xD;
          -  Documented allergy to DMSO, mouse or bovine proteins, or iron.&#xD;
&#xD;
          -  Subject has other conditions that in the opinion of the investigator would place the&#xD;
             subject at increased risk for toxicity by participation in the study.&#xD;
&#xD;
          -  Psychiatric condition making the patient unlikely to comply with protocol therapy,&#xD;
             required tests and follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Finegan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiocrine Bioscience</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliet Barker, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

